BlossomHill Therapeutics (NASDAQ:BLSM) Shares Up 8.1% – Here’s What Happened

Posted by Francis Steltz on Oct 28th, 2026

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM – Get Free Report)’s share price was up 8.1% on Monday. The company traded as high as $15.97 and last traded at $15.81. 63,808 shares traded hands during mid-day trading, a decline of 69% from the average daily volume of 205,333 shares. The stock had previously closed at $14.63.

Analyst Ratings Changes

Several research analysts have issued reports on BLSM shares. Lifesci Capital initiated coverage on BlossomHill Therapeutics in a report on Tuesday, September 1st. They set an “outperform” rating and a $32.00 price objective on the stock. HC Wainwright reiterated a “buy” rating on shares of BlossomHill Therapeutics in a research report on Wednesday, September 30th. Zacks Research raised BlossomHill Therapeutics to a “hold” rating in a research note on Wednesday, September 2nd. JPMorgan Chase & Co. initiated coverage on BlossomHill Therapeutics in a research report on Tuesday, September 1st. They set an “overweight” rating and a $28.00 target price for the company. Finally, Leerink Partners boosted their target price on BlossomHill Therapeutics from $36.00 to $40.00 and gave the stock an “outperform” rating in a research report on Monday, September 21st. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, BlossomHill Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $35.00.

View Our Latest Stock Report on BLSM

BlossomHill Therapeutics Trading Up 3.7%

The firm has a market cap of $519.37 million and a P/E ratio of -1.87. The firm has a 50-day moving average of $19.03.

BlossomHill Therapeutics (NASDAQ:BLSM – Get Free Report) last announced its quarterly earnings data on Friday, September 18th. The company reported ($8.75) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($7.91). On average, sell-side analysts anticipate that BlossomHill Therapeutics, Inc. will post -5.54 EPS for the current fiscal year.

Insider Buying and Selling at BlossomHill Therapeutics

In related news, Director Bihua Chen purchased 312,500 shares of the stock in a transaction dated Monday, August 10th. The stock was bought at an average cost of $16.00 per share, with a total value of $5,000,000.00. Following the purchase, the director directly owned 3,614,034 shares in the company, valued at $57,824,544. The trade was a 9.47% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Carl L. Gordon purchased 625,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the transaction, the director directly owned 2,714,279 shares in the company, valued at $43,428,464. This trade represents a 29.91% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 1,573,900 shares of company stock valued at $25,181,900 over the last quarter.

About BlossomHill Therapeutics

(Get Free Report)

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.